CLOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clover Health Investments Corp (CLOV) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company has shown significant revenue growth and improved financials, the technical indicators are bearish, insider selling is high, and there are no recent positive news catalysts or strong trading signals to suggest immediate upside potential. Holding off on a purchase until more favorable conditions emerge would be prudent.
The technical indicators are bearish. The MACD is negatively expanding below zero (-0.00766), the RSI is at an oversold level (16.132), and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 1.802), with resistance levels at R1: 1.993 and R2: 2.052.
Additionally, Clover Health is benefiting from favorable 2026 rates from CMS and being paid as a 4-star plan, which analysts find compelling.
Insider selling has increased significantly (2175.53% over the last month), and there are no recent news catalysts. The stock's technical indicators are bearish, and hedge funds remain neutral. Analyst price targets have been lowered recently, reflecting cautious sentiment.
In Q3 2025, Clover Health's revenue increased to $496.65 million (up 50.05% YoY), net income improved to -$24.38 million (up 166.27% YoY), and EPS increased to -0.05 (up 150% YoY). Gross margin remained flat at 100%.
Canaccord maintains a Buy rating with a lowered price target of $3.20 (from $3.70), citing strong tailwinds for 2026. UBS maintains a Neutral rating with a lowered price target of $2.75 (from $3), reflecting cautious optimism.
